Literature DB >> 20022530

Pyruvate dehydrogenase E2 deficiency: a potentially treatable cause of episodic dystonia.

Catherine A McWilliam1, Cheryl K Ridout, Ruth M Brown, Robert C McWilliam, John Tolmie, Garry K Brown.   

Abstract

The association of progressive episodic dystonia and learning disability with distinctive neuroimaging findings may lead to consideration of atypical Pantothenate Kinase Associated Neurodegeneration (PKAN) and investigations directed towards that diagnosis. Recent reports indicate that deficiency of dihydrolipoamide acetyltransferase, the E2 component of the pyruvate dehydrogenase complex, may present similarly, and that this disorder should also be considered in the differential diagnosis. We describe two sisters with early onset episodic dystonia and pyruvate dehydrogenase deficiency caused by defects in the E2 subunit. Both have neuroimaging features similar to previously described patients and have mutations in the DLAT gene. As this condition is potentially treatable with a ketogenic diet, the possibility of this diagnosis should be considered in similar cases. Copyright (c) 2009 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022530     DOI: 10.1016/j.ejpn.2009.11.001

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  15 in total

Review 1.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2011-10-07       Impact factor: 4.797

2.  ADCY5 mutation carriers display pleiotropic paroxysmal day and nighttime dyskinesias.

Authors:  Jennifer R Friedman; Aurélie Méneret; Dong-Hui Chen; Oriane Trouillard; Marie Vidailhet; Wendy H Raskind; Emmanuel Roze
Journal:  Mov Disord       Date:  2015-12-21       Impact factor: 10.338

3.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2012-07       Impact factor: 4.797

Review 4.  Paroxysmal Movement Disorders: Recent Advances.

Authors:  Zheyu Xu; Che-Kang Lim; Louis C S Tan; Eng-King Tan
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-11       Impact factor: 5.081

5.  Pyruvate dehydrogenase complex-E2 deficiency causes paroxysmal exercise-induced dyskinesia.

Authors:  Jennifer Friedman; Annette Feigenbaum; Nathaniel Chuang; Jennifer Silhavy; Joseph G Gleeson
Journal:  Neurology       Date:  2017-11-01       Impact factor: 9.910

Review 6.  Genetic updates on paroxysmal dyskinesias.

Authors:  James Y Liao; Philippe A Salles; Umar A Shuaib; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-30       Impact factor: 3.575

Review 7.  The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders.

Authors:  Wolfgang Sperl; Leanne Fleuren; Peter Freisinger; Tobias B Haack; Antonia Ribes; René G Feichtinger; Richard J Rodenburg; Franz A Zimmermann; Johannes Koch; Isabel Rivera; Holger Prokisch; Jan A Smeitink; Johannes A Mayr
Journal:  J Inherit Metab Dis       Date:  2014-12-20       Impact factor: 4.982

Review 8.  Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features.

Authors:  Serena Galosi; Francesca Nardecchia; Vincenzo Leuzzi
Journal:  Mov Disord Clin Pract       Date:  2020-02-04

9.  Phenylbutyrate increases pyruvate dehydrogenase complex activity in cells harboring a variety of defects.

Authors:  Rosa Ferriero; Audrey Boutron; Michele Brivet; Douglas Kerr; Eva Morava; Richard J Rodenburg; Luisa Bonafé; Matthias R Baumgartner; Yair Anikster; Nancy E Braverman; Nicola Brunetti-Pierri
Journal:  Ann Clin Transl Neurol       Date:  2014-06-19       Impact factor: 4.511

Review 10.  Regulation of pyruvate metabolism and human disease.

Authors:  Lawrence R Gray; Sean C Tompkins; Eric B Taylor
Journal:  Cell Mol Life Sci       Date:  2013-12-21       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.